LataMed AI Corp. (OTC: LMED), a development-stage digital health and artificial intelligence technology company, announced continued progress on its mobile healthcare application ecosystem, including applications being prepared for future availability through the Apple App Store and Google Play Store. The company also reported surpassing 1,000 early-stage platform subscribers, a milestone it views as validation of early interest in its technology.
The applications under development are designed to support telehealth, healthcare communication, patient engagement, provider coordination, emergency response, and AI-assisted healthcare initiatives as part of LataMed AI's broader digital healthcare infrastructure strategy. The company is focusing on emerging markets, particularly Latin America, where access to healthcare coordination and digital tools remains limited.
Management stated that the applications are undergoing continued development, testing, integration, and optimization. Certain applications are being readied for submission to Apple and Google platforms, pending further development, internal testing, platform reviews, and regulatory considerations. No specific timeline for public release has been provided.
Dr. Kevin Rodan Levy, Chief Executive Officer of LataMed AI Corp., said: “We are continuing to advance development of our mobile healthcare application ecosystem with the goal of expanding accessibility and healthcare connectivity through both Apple and Android mobile platforms. Surpassing 1,000 early-stage users represents an encouraging milestone as we continue refining and expanding our broader digital healthcare infrastructure initiatives.”
The company believes that continued user onboarding and engagement will provide valuable operational feedback as development progresses. LataMed AI's broader technology initiatives remain focused on scalable healthcare infrastructure solutions for underserved markets.
The applications and related platform technologies remain under active development and have not yet been fully commercialized. No assurance can be given regarding the timing of public release, App Store or Google Play availability, regulatory progression, or operational success. For more information, visit https://latamed.ai or review the company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.
